Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 25, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Expert physicians consider the recent treatment approvals for the management of acute migraine, and how the shift in expectations outcomes has impacted treatment selection.
This specialty series is dedicated to assessing the impact COVID-19 has had on the quality of life of patients with neurological disorders and the clinicians who were forced to adapt during this unique era of medical history.
The pandemic's impact stretches across all aspects of life and has particularly concerning effects on the sleep of those working on the frontlines providing care of patients.
M. Scott Perry, MD, discusses historically approved therapies for the first-, second-, and third-line treatment of Dravet syndrome.
Jason M. Schwalb, MD; Ellen L. Air, MD, PhD; Neepa J. Patel, MD; and Julia A. Wall discuss Henry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care that has helped it become a leading treatment center for Parkinson disease and related movement disorders.